Medivation, Inc. (Nasdaq: MDVN) presented new data that provide additional evidence that Dimebon, its lead product candidate in development to treat Alzheimer's and Huntington's diseases, potentially operates via a novel mitochondrial mechanism of action. In preclinical studies, Dimebon was shown to impact two key aspects of brain cell function: it promoted neurite outgrowth and it preserved mitochondrial function after brain cells were challenged with beta amyloid, a toxic substance often associated with Alzheimer's disease and the loss of brain cells. I am excited. Countdown for the cure will soon end.
Tuesday, December 9, 2008
Medivation Presents New Data on Dimebon's Novel Mechanism of Action
Posted by Heather Dugdale at 9:36 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment